Ungerechts Lab

Guy Ungerechts profile picture

Contact Information

Guy Ungerechts, MD, PhD

gungerechts@ohri.ca

Ottawa Hospital Research Institute
Center for Cancer Therapeutics
501 Smyth Rd. Box 926,
Ottawa, On, K1H 8L6

What We Do


The group of Dr. Ungerechts investigates innovative methods to destroy cancer cells and stimulate the patient’s immune system to attack tumors while leaving healthy tissues unharmed.

Therefore, Dr. Ungerechts and his team genetically modify viruses for selective replication in and lysis of tumor cells. These oncolytic viruses (OVs) can transport therapeutic transgenes (e.g., antibodies or cytokines) directly to the tumor. Besides, virus-induced lysis of cancer cells strongly stimulates the immune system which in turn can recognize and attack the tumor. The main research areas are: First, the development of novel immunovirotherapy approaches, i.e. the combination of immunotherapy (e.g., tumor vaccination or checkpoint inhibition) and (prime-boost) OV treatment, and, second, the genetic engineering of next-generation OVs with improved safety and efficacy (by, e.g., microRNA-based modification of vector tropism or novel therapeutic transgenes).

Having received the Ontario Institute for Cancer Research Investigator Award for Clinician Scientists (in 2015), the Terry Fox New Investigator Award (in 2016), and being part of the Canadian Oncolytic Virus Consortium (COVCo), Guy Ungerechts develops these innovative treatments in cooperation with Dr. John Bell, Senior Scientist at the OHRI and COVCo Lead Investigator. As a Clinician Scientist, Dr. Ungerechts explicitly aims at the near-term translation of OV-based therapies from the laboratory into clinical trials.

Selected Publications


Targeted BiTE Expression by an Oncolytic Vector Augments Therapeutic Efficacy Against Solid Tumors.
Speck T, Heidbuechel JPW, Veinalde R, Jaeger D, von Kalle C, Ball CR, Ungerechts G, Engeland CE.
Clin Cancer Res. 2018 May 1;24(9):2128-2137. 

Enhanced Control of Oncolytic Measles Virus Using MicroRNA Target Sites.
Leber MF, Baertsch MA, Anker SC, Henkel L, Singh HM, Bossow S, Engeland CE, Barkley R, Hoyler B, Albert J, Springfeld C, Jäger D, von Kalle C, Ungerechts G.
Mol Ther Oncolytics. 2018 Apr 12;9:30-40.

Oncolytic measles virus encoding interleukin-12 mediates potent antitumor effects through T cell activation.
Veinalde R, Grossardt C, Hartmann L, Bourgeois-Daigneault MC, Bell JC, Jäger D, von Kalle C, Ungerechts G, Engeland CE.
Oncoimmunology. 2017 Jan 31;6(4):e1285992.

CTLA-4 and PD-L1 Checkpoint Blockade Enhances Oncolytic Measles Virus Therapy.
Engeland CE, Grossardt C, Veinalde R, Bossow S, Lutz D, Kaufmann JK, Shevchenko I, Umanksy V, Nettelbeck DM, Weichert W, Jäger D, von Kalle C, Ungerechts G.
Mol Ther. 2014 Nov;22(11):1949-59.

GM-CSF-armed oncolytic measles virus is an effective therapeutic cancer vaccine.
Grossardt C, Engeland CE, Bossow S, Halama N, Zaoui K, Leber MF, Springfeld C, Jaeger D, von Kalle C, Ungerechts G.
Hum Gene Ther. 2013 Jul;24(7):644-54.

Chemovirotherapy of malignant melanoma with a targeted and armed oncolytic measles virus.
Kaufmann JK, Bossow S, Grossardt C, Sawall S, Kupsch J, Erbs P, Hassel JC, von Kalle C, Enk AH, Nettelbeck DM, Ungerechts G.
J Invest Dermatol. 2013 Apr;133(4):1034-42. 

Armed and targeted measles virus for chemovirotherapy of pancreatic cancer.
Bossow S, Grossardt C, Temme A, Leber MF, Sawall S, Rieber EP, Cattaneo R, von Kalle C, Ungerechts G.
Cancer Gene Ther. 2011 Aug;18(8):598-608.

MicroRNA-sensitive oncolytic measles viruses for cancer-specific vector tropism.
Leber MF, Bossow S, Leonard VH, Zaoui K, Grossardt C, Frenzke M, Miest T, Sawall S, Cattaneo R, von Kalle C, Ungerechts G.
Mol Ther. 2011 Jun;19(6):1097-106.

Meet the Ungerechts Lab


Dr. Ungerechts is heading a second research group at the National Center for Tumor Diseases (NCT) in Heidelberg, Germany.
Click here to find out more about the laboratory in Heidelberg.